 These days, several monoclonal antibodies neutralizing IL-17A have potential for the treatment of autoimmune diseases in humans, such as plaque psoriasis.Majority of these monoclonal antibodies are humanized IgG1.This therapy may also be soon used for protection against periodontal bone loss as it is currently being tested in mice.